Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients: A Single-arm, Phase II Single-center Trial

NCT05463224 is registered in ClinicalTrials.gov with Sehhoon Park as lead sponsor.

NCT NCT05463224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05463224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients: A Single-arm, Phase II Single-center Trial
Lead sponsor
Sehhoon Park
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 4, 2023
Completion date
December 31, 2027
Enrollment
150 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc